Fasano A (febrero de 2012). «Leaky gut and autoimmune diseases». Clin Rev Allergy Immunol (Revisión) 42 (1): 71-8. PMID22109896. doi:10.1007/s12016-011-8291-x. «Besides celiac disease, several other autoimmune diseases, including type 1 diabetes [13, 14], multiple sclerosis [15, 16], and rheumatoid arthritis [17], are characterized by increased intestinal permeability secondary to noncompetent TJs that allow the passage of antigens from the intestinal flora, challenging the immune system to produce an immune response that can target any organ or tissue in genetically predisposed individuals [18–21]. Además de la enfermedad celíaca, varias otras enfermedades autoinmunes, incluyendo la diabetes tipo 1 [13, 14], la esclerosis múltiple [15, 16], y la artritis reumatoide [17], se caracterizan por aumento de la permeabilidad intestinal secundaria a uniones estrecha no competentes que permiten el paso de antígenos de la flora intestinal, desafiando el sistema inmune para producir una respuesta inmune que puede dirigirse a cualquier órgano o tejido en individuos genéticamente predispuestos [18-21].».
Dos Santos S, Lioté F (mayo de 2017). «Osteoarticular manifestations of celiac disease and non-celiac gluten hypersensitivity.». Joint Bone Spine (Revisión) 84 (3): 263-266. PMID27825568. doi:10.1016/j.jbspin.2016.09.007. «Celiac disease and rheumatoid arthritis (RA). RA and celiac disease share similar pathophysiological mechanisms. Features common to both diseases include epidemiological trends, autoantibodies and genes, associated environmental inducers, and a gut microbiota imbalance with increased gut permeability. Gastrointestinal manifestations occur in patients with RA and rheumatic manifestations in those with celiac disease.»
Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936-9. doi: 10.1016/j.amjmed.2007.04.005. PMID 17976416
Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective on the etiology of rheumatoid arthritis. Hand Clin. 2011;27(1):1-10. doi: 10.1016/j.hcl.2010.09.006. PMID 21176794
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. PMID 3358796
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–81. PMID 20872595
Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of Rheumatoid Arthritis - A Comprehensive Review. Clinic Rev Allerg Immunol. 2013;45(2):170-179. doi: 10.1007/s12016-012-8346-7. PMID 23288628.
Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999; 97(2): 188–96. doi: 10.1046/j.1365-2567.1999.00772. PMID 10447731 x
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376(9746):1094-108. doi = 10.1016/S0140-6736(10)60826-4. PMID 20870100
Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46. PMID 16385494
Takagi H, Ishiguro N, Iwata H, Kanamono T. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol. 2000;27(7):1638-42. PMID 10914844
Tengstrand B, Carlström K, Hafström I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. heumatology (Oxford). 2002;41(3):285-9. PMID 11934965
Ruiz-Esquide V, Sanmartí R. Tabaco y otros factores ambientales en la artritis reumatoide. Reumatol Clin. 2012;8(6):342-50. doi: 10.1016/j.reuma.2012.02.011. PMID 22609003
Mikuls TR. Help stop tooth decay...and prevent RA? J Rheumatol. 2010;37(6):1083-5. doi: 10.3899/jrheum.100173. PMID 20516033
Scher JU, Bretz WA, Abramson SB. Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors? Curr Opin Rheumatol. 2014;26(4):424-9. doi: 10.1097/BOR.0000000000000076. PMID 24807405
Fasano A (febrero de 2012). «Leaky gut and autoimmune diseases». Clin Rev Allergy Immunol (Revisión) 42 (1): 71-8. PMID22109896. doi:10.1007/s12016-011-8291-x. «Besides celiac disease, several other autoimmune diseases, including type 1 diabetes [13, 14], multiple sclerosis [15, 16], and rheumatoid arthritis [17], are characterized by increased intestinal permeability secondary to noncompetent TJs that allow the passage of antigens from the intestinal flora, challenging the immune system to produce an immune response that can target any organ or tissue in genetically predisposed individuals [18–21]. Además de la enfermedad celíaca, varias otras enfermedades autoinmunes, incluyendo la diabetes tipo 1 [13, 14], la esclerosis múltiple [15, 16], y la artritis reumatoide [17], se caracterizan por aumento de la permeabilidad intestinal secundaria a uniones estrecha no competentes que permiten el paso de antígenos de la flora intestinal, desafiando el sistema inmune para producir una respuesta inmune que puede dirigirse a cualquier órgano o tejido en individuos genéticamente predispuestos [18-21].».
Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford). 2014 May 15. pii: keu195. [Epub ahead of print] PMID 24831057
Klareskog L, Amara K, Malmström V. Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol. 2014;26(1):72-9. doi: 10.1097/BOR.0000000000000016. PMID 24257366
Paula FS, Alves JD. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics. 2014;8:1-12. doi: 10.2147/BTT.S35475. PMID 24353404
Pablos Álvarez JL. Participación de los linfocitos T en el desarrollo y perpetuación de la artritis reumatoide. Reumatol Clin. 2011;7(6):352-3. doi: 10.1016/j.reuma.2010.12.010. PMID 22078692
Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol. 2014;44(2):339-47. doi: 10.1002/eji.201344184. PMID 24310226
Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol. 2014;26(2):204-10. doi: 10.1097/BOR.0000000000000036. PMID 24445478
Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003)."Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years". Ann Rheum Dis. 62 (8): 722-7.doi:10.1136/ard.62.8.722. PMID 12860726
Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11(2):123-31. doi: 10.1016/j.autrev.2011.09.001. PMID 21939785
Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007;120(11):936-9. PMID 17976416
Bloxham E, Vagadia V, Scott K, et al. Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad Med J. 2011;87(1031):596-600. doi: 10.1136/pgmj.2011.117507. PMID 21659451
Möller B, Scherer A, Förger F, et al. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis. 2014 Apr;73(4):691-6. doi: 10.1136/annrheumdis-2012-202709. PMID 23505235
Estrada CA, Lyons S, Terebelo H. Autoimmune hemolytic anemia and rheumatoid arthritis. South Med J. 1990;83(5):599-600. PMID 2343338
Pérez-Dórame R, Mejía M, Mateos-Toledo H, Rojas-Serrano J. Rheumatoid arthritis-associated interstitial lung disease: Lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity.Reumatol Clin. 2014 Jun 6. pii: S1699-258X(14)00054-0. doi: 10.1016/j.reuma.2014.02.007. PMID 24913966
Fischer A, Cosgrove GP. Interstitial lung abnormalities in rheumatoid arthritis are common and important. Chest. 2014;146(1):8-10. doi: 10.1378/chest.14-0030. PMID 25010956
Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-12. doi: 10.1002/art.38322. PMID 24757133
Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74(4):443-50. doi: 10.1007/s40265-014-0190-z. PMID 24570384
Abud-Mendoza C, Cuevas-Orta E. Interstitial lung disease (ILD) in rheumatoid arthritis (RA). Rev Invest Clin. 2013;65(5):455-6. PMID 24687345
Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med. 2014;35(2):222-38. doi: 10.1055/s-0034-1371542. PMID 24668537.
Bartels CM, Bridges AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments? Curr Rheumatol Rep. 2010;12(6):414-9. doi: 10.1007/s11926-010-0130-1. PMID 20842467
He J, Ding Y, Feng M, et al. Characteristics of Sjögren's syndrome in rheumatoid arthritis. Rheumatology (Oxford). 2013;52(6):1084-9. doi: 10.1093/rheumatology/kes374. PMID 23382356
Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):907-27. PMID 17870035
González-Gay MA, González-Juanatey C. Inflammation and lipid profil in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014;73(7):1281-3. doi: 10.1136/annrheumdis-2013-204933. PMID 24907362
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008:59 (12):1690-1697. doi:10.1002/art.24092. PMID 19035419
Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):283-303. PMID 11396093
Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24(6):733-45. doi: 10.1016/j.berh.2010.10.001. PMID 21665122
Radic M, Martinovic Kaliterna D, Radic J. Overview of vasculitis and vasculopathy in rheumatoid arthritis--something to think about. Clin Rheumatol. 2013;32(7):937-42. doi: 10.1007/s10067-013-2273-8. PMID 23649484
Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014 Jun 6. pii: keu224. [Epub ahead of print] PMID 24907149
Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma. 2008;8(2):87-93. doi: 10.3816/CLM.2008.n.009. PMID 18501101
Dos Santos S, Lioté F (mayo de 2017). «Osteoarticular manifestations of celiac disease and non-celiac gluten hypersensitivity.». Joint Bone Spine (Revisión) 84 (3): 263-266. PMID27825568. doi:10.1016/j.jbspin.2016.09.007. «Celiac disease and rheumatoid arthritis (RA). RA and celiac disease share similar pathophysiological mechanisms. Features common to both diseases include epidemiological trends, autoantibodies and genes, associated environmental inducers, and a gut microbiota imbalance with increased gut permeability. Gastrointestinal manifestations occur in patients with RA and rheumatic manifestations in those with celiac disease.»
Albrecht K. Gender-specific differences in comorbidities of rheumatoid arthritis. Z Rheumatol. 2014 Jun 19. [Epub ahead of print]. PMID 24939007
Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845–51. doi:10.1136/ard.2006.051391. PMID 16606649
Chandrashekara S, Sachin S. Measures in rheumatoid arthritis: are we measuring too many parameters. Int J Rheum Dis. 2012;15(3):239-48. doi: 10.1111/j.1756-185X.2012.01754.x. PMID 22709486
Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640-7. doi: 10.1002/acr.21649. PMID 22473918
Chorus AM, Miedema HS, Wevers CJ, van Der Linden S. Labour force participation among patients with rheumatoid arthritis. Ann Rheum Dis. 2000;59(7):549-54. PMID 10873966
Myasoedova E, Davis JM 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379-85. doi: 10.1007/s11926-010-0117-y. PMID 20645137
Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39. doi: 10.1002/acr.21641. PMID 22473917
Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2014 Apr 4. doi: 10.1136/annrheumdis-2013-204601. [Epub ahead of print] PMID 24706006.
Lanas A, Benito P, Alonso J, et al. Safe prescription recommendations for nonsteroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG). Reumatol Clin. 2014;10(2):68-84. doi: 10.1016/j.reuma.2013.10.004. PMID 24462644.
Radner H, Ramiro S, Buchbinder R, Landewé RB, van der Heijde D, Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database Syst Rev. 2012;1:CD008951. doi: 10.1002/14651858.CD008951.pub2. PMID 22258995
Marks JL, Colebatch AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD008952. doi: 10.1002/14651858.CD008952.pub2. PMID 21975789
Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(11):1-278, iii. PMID 18405470
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2. doi: 10.1186/ar4174. PMID 24267197
No figuran autores. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs. Prescrire Int. 2011;20(119):216-9. PMID 21954519
Gaujoux-Viala C, Gossec L. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Ann N Y Acad Sci. 2014;1318:32-40. doi: 10.1111/nyas.12452. PMID 24827544
Makol A, Davis JM 3rd, Crowson CS, Therneau TM, Gabriel SE, Matteson EL. Time trends in glucocorticoid use in rheumatoid arthritis: Results from a population based inception cohort 1980-1994 vs. 1995-2007. Arthritis Care Res (Hoboken). 2014 May 12. doi: 10.1002/acr.22365. [Epub ahead of print] PMID 24821680
Blanco-Morales EA, Bravo-Ferrer JM, Rubio Romero E, Gil González E, Gantes Pedraza MÁ. Glucocorticoides en artritis reumatoide: ¿casi siempre o casi nunca? Reumatol Clin. 2011;7(6):407-11. doi: 10.1016/j.reuma.2011.01.008. PMID 22078702
Rau R. Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother. 2014;15(11):1575-83. doi: 10.1517/14656566.2014.922955. PMID 24856989.
Kissin EY. The "Dirty Little Secret" Exposed in the 2013 EULAR Recommendations for rheumatoid arthritis therapy. Clin Ther. 2014. pii: S0149-2918(14)00375-0. doi: 10.1016/j.clinthera.2014.06.012. PMID 24996488
Hetland ML, Hørslev-Petersen K. The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S44-9. PMID 23079125.
Gvozdenović E, Dirven L, van den Broek M, et al. Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study. Clin Rheumatol. 2014;33(2):263-7. doi: 10.1007/s10067-013-2465-2. PMID 24384824.
Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.J Rheumatol. 2014;41(6):1049-60. doi: 10.3899/jrheum.130738. PMID 24737913
Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014 Jul 1. [Epub ahead of print] PMID 24983446
Tornero Molina J, Ballina García FJ, Calvo Alén J, et al. Recomendaciones para el uso de metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración. Reumatol Clin. 2014 Apr 16. pii: S1699-258X(14)00059-X. doi: 10.1016/j.reuma.2014.02.012. [Epub ahead of print]. PMID 24746914
Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10;6:CD000957. doi: 10.1002/14651858.CD000957.pub2. PMID 24916606.
Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis Trial Investigator Group. Arthritis Rheum. 2001;44(9):1984-92. PMID 11592358
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. PMID 24161836
Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12(1):102. PMID 24988902
Hirabara S, Takahashi N, Fukaya N, et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol. 2014 Jun 28. [Epub ahead of print] PMID 24970596.
Curtis JR, Schabert VF, Harrison DJ, et al. Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a Validated Algorithm to Commercial Insurance Claims. Clin Ther. 2014 Jul 7. pii: S0149-2918(14)00352-X. doi: 10.1016/j.clinthera.2014.05.062. PMID 25012729.
Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The Comparative Safety of TNF Inhibitors in Rheumatoid Arthritis - A Meta-Analysis Update of 44 Randomized Controlled Trials. Am J Med. 2014 Jun 17. pii: S0002-9343(14)00488-4. doi: 10.1016/j.amjmed.2014.06.012. PMID 24950486.
Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther. 2014;36(5):737-47. doi: 10.1016/j.clinthera.2014.02.019. PMID 24661783.
Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013;1(2):177-184. PMID 24648915
Wendler J, Burmester GR, Sörensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): 6-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014 Mar 26;16(2):R80. [Epub ahead of print] PMID 24670196
Richter A, Strangfeld A, Herzer P, et al. Sustainability of rituximab therapy in different treatment strategies - results of a 3-year follow-up of the German biologics register RABBIT. Arthritis Care Res (Hoboken). 2014 Mar 24. doi: 10.1002/acr.22327. PMID 24664818
Nakashima Y, Kondo M, Fukuda T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. Mod Rheumatol. 2014;24(2):258-64. doi: 10.3109/14397595.2013.854069. PMID 24593201
Álvaro-Gracia JM, Fernández-Nebro A, García-López A, et al. Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clínica habitual. Reumatol Clin. 2014;10(2):94-100. doi: 10.1016/j.reuma.2013.07.002. PMID 24099961
Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics. 2009;3:485-98. PMID 20054439
Wells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. Biologics. 2014;8:41-55. doi: 10.2147/BTT.S55783. PMID 24600202
Genovese MC, Tena CP, Covarrubias A, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol. 2014;41(4):629-39. doi: 10.3899/jrheum.130112. PMID 24584926
Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837-52. doi 10.3899/jrheum.130683. PMID 24692527
Nikiphorou E, Carpenter L, Morris S, et al. "Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts." Arthritis Rheumatol. 2014;66(5):1081-9. doi 10.1002/art.38344. PMID24782174
Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012;107 Suppl 2:S171-84. doi: 10.1017/S0007114512001560. PMID 22591891
Soeken K L, Miller S A, Ernst E. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2003;42(5):652-9. PMID 12709541.
Lv QW, Zhang W, Shi Q, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2014 Apr 14. doi: 10.1136/annrheumdis-2013-204807. [Epub ahead of print] PMID 24733191
Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E, el al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines inrheumatoid arthritis patients: a randomized double-blind clinical trial. Int J Rheum Dis. 2014 Mar 27. doi: 10.1111/1756-185X.12333. [Epub ahead of print] PMID 24673738
Schur PH, Gabriel SE, Crowson CS. Epidemiology of, risk factors for, and posible causes of rheumatoid arthritis. UpToDate 2014. http://www.uptodate.com
Schur PH, Firenstein GS. Pathogenesis of rheumatoid arthritis. UpToDate 2014. http://www.uptodate.com
Venables PJW, Maini RN. Disease outcome and functional capacity in rheumatoid arthritis. UpToDate 2014. http://www.uptodate.com
Venables PJW, Maini RN. Diagnosis and differential diagnosis of rheumatoid arthritis. UpToDate 2014. http://www.uptodate.com
